GDTC

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

CytoMed Therapeutics Limited Ordinary Shares

NASDAQ | GDTC

2.06

USD

$0.00

(

0.00%

)

At Close (As of Oct 10, 2025)

$24.17M

Market Cap

-

P/E Ratio

-0.25

EPS

$4.05

52 Week High

$1.65

52 Week Low

HEALTHCARE

Sector

GDTC Chart

Recent Chart
Price Action

GDTC Technicals

Tags:

GDTC Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (SGD)
Gross Profit $52K
Total Revenue $52K
Cost Of Revenue $23K
Costof Goods And Services Sold $23K
Operating Income -$2.6M
Selling General And Administrative $1.2M
Research And Development $1.4M
Operating Expenses $1.9M
Investment Income Net -
Net Interest Income $297K
Interest Income $318K
Interest Expense $15K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $92K
Income Before Tax -$1.9M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$2.5M
Comprehensive Income Net Of Tax -
Ebit -$1.9M
Ebitda -$1.8M
Net Income -$1.9M

Revenue & Profitability

Earnings Performance

GDTC Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (SGD)
Total Assets $7.4M
Total Current Assets $4.4M
Cash And Cash Equivalents At Carrying Value $3.6M
Cash And Short Term Investments $3.6M
Inventory $614K
Current Net Receivables $14K
Total Non Current Assets $3M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $68K
Intangible Assets Excluding Goodwill $68K
Goodwill $260
Investments -
Long Term Investments $221K
Short Term Investments $200K
Other Current Assets $126K
Other Non Current Assets -
Total Liabilities $750K
Total Current Liabilities $444K
Current Accounts Payable $28K
Deferred Revenue -
Current Debt -
Short Term Debt $34K
Total Non Current Liabilities $306K
Capital Lease Obligations $31K
Long Term Debt $394K
Current Long Term Debt $38K
Long Term Debt Noncurrent -
Short Long Term Debt Total $339K
Other Current Liabilities $382K
Other Non Current Liabilities -
Total Shareholder Equity $6.6M
Treasury Stock -
Retained Earnings -$11M
Common Stock $17M
Common Stock Shares Outstanding $12M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (SGD)
Operating Cashflow -$1.7M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $246K
Capital Expenditures $1M
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $495K
Cashflow From Financing -$33K
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout $0
Dividend Payout Common Stock $0
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$1.8M

yearly Income Statement (As of Dec 31, 2024)

Field Value (SGD)
Gross Profit $52K
Total Revenue $52K
Cost Of Revenue $23K
Costof Goods And Services Sold $23K
Operating Income -$2.6M
Selling General And Administrative $1.2M
Research And Development $1.4M
Operating Expenses $1.9M
Investment Income Net -
Net Interest Income $297K
Interest Income $318K
Interest Expense $15K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $92K
Income Before Tax -$1.9M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$2.5M
Comprehensive Income Net Of Tax -
Ebit -$1.9M
Ebitda -$1.8M
Net Income -$1.9M

GDTC News

GDTC Profile

CytoMed Therapeutics Limited Ordinary Shares Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

CytoMed Therapeutics Limited (GDTC) is an innovative pre-clinical biopharmaceutical company based in Singapore, dedicated to harnessing the power of novel cell-based immunotherapies to combat human cancers. With a strong emphasis on developing proprietary therapeutic candidates, CytoMed aims to address unmet medical needs in oncology through cutting-edge technology and research. The company's commitment to advancing its therapeutic pipeline positions it at the forefront of the rapidly evolving field of cancer immunotherapy, appealing to institutional investors seeking opportunities in the biopharmaceutical sector.

VHAI
-25.00%
$0.00
YYAI
-12.69%
$0.16
STAI
+39.44%
$0.62
CGBS
-39.47%
$0.03
BURU
+6.25%
$0.50
PLUG
+13.30%
$3.87
ELBM
+334.95%
$7.17
GWH
+149.66%
$10.38
RGTI
+20.26%
$52.82
NVDA
+2.98%
$188.62
ASST
-35.33%
$1.00
BITF
+25.47%
$5.26
IONZ
-35.04%
$2.21
BYND
-47.01%
$1.06
NVTS
+23.51%
$10.16
JOBY
+2.94%
$16.76
DNN
+6.94%
$3.07
CAN
+33.93%
$1.45
SNAP
-7.15%
$7.78
QBTS
+23.97%
$40.93
INTC
+2.03%
$37.11
GPUS
-12.50%
$0.41
WULF
-0.58%
$13.51
F
+1.27%
$11.55
AXDX
-61.36%
$0.03
BBD
+1.30%
$3.10
CLF
+4.66%
$13.79
TSLA
+5.01%
$434.23
QS
+16.36%
$17.10
CRML
+56.07%
$23.38
NIO
+6.59%
$7.15
ETHD
-11.62%
$3.37
ACHR
+6.09%
$12.70
AMD
+0.40%
$215.76
PWM
+12.50%
$1.17
SOUN
+10.25%
$19.14
RXRX
+4.41%
$5.55
CIFR
+19.77%
$20.32
MP
+21.94%
$95.52
LAES
+13.49%
$6.14
APLD
+2.14%
$34.71
BTBT
+5.58%
$3.97
SOFI
+4.45%
$27.35
DVLT
-12.36%
$1.66
TLRY
+0.58%
$1.73
USAR
+17.01%
$38.15
DFLI
+41.35%
$1.54
ONDS
+18.43%
$10.92
PFE
-0.30%
$24.70
RR
+7.85%
$6.38
WBD
-3.22%
$17.10
QUBT
+12.85%
$21.46
ABAT
+33.25%
$8.99
NAK
+26.47%
$2.56
UAMY
+35.91%
$16.59
RMBL
+60.50%
$3.21
EOSE
+23.62%
$17.08
IREN
+8.04%
$64.58
EPWK
-8.00%
$0.08
ADD
-25.47%
$0.05
ADAP
-0.64%
$0.18
CORZ
+2.66%
$18.52
UUUU
+18.40%
$24.08
AAL
+1.51%
$11.69
RIG
+3.24%
$3.18
MARA
+9.43%
$20.40
TMQ
-9.46%
$5.93
NAKA
-4.05%
$0.83
PLTR
+0.84%
$176.92
SRM
+53.27%
$10.30
NOK
-1.79%
$5.22
IONQ
+18.72%
$83.88
RF
+1.75%
$24.58
BMNR
+7.40%
$56.35
GDXD
-12.99%
$0.74
XCH
+119.76%
$1.81
T
-1.06%
$25.59
QSI
+26.28%
$2.10
BULL
+1.62%
$11.58
NB
+3.81%
$10.78
CLSK
+2.49%
$19.76
BINI
-55.00%
$0.63
MULN
-55.00%
$0.63
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
AMZN
+1.81%
$220.30
AVGO
-5.90%
$324.63
NEHC
-8.12%
$2.60
WLGS
-5.57%
$0.04
BTG
+3.87%
$5.27
WWR
0.00%
$1.98
KDLY
-7.21%
$0.87
AMC
+0.68%
$2.95
ETWO
0.00%
$3.30
AAPL
+1.24%
$248.32
HOOD
+1.03%
$140.40
PMAX
+44.78%
$3.75
HPE
+2.76%
$25.07
TMC
+18.40%
$10.52
ABEV
+1.42%
$2.14
VHAI
-25.00%
$0.00
YYAI
-12.69%
$0.16
STAI
+39.44%
$0.62
CGBS
-39.47%
$0.03
BURU
+6.25%
$0.50
PLUG
+13.30%
$3.87
ELBM
+334.95%
$7.17
GWH
+149.66%
$10.38
RGTI
+20.26%
$52.82
NVDA
+2.98%
$188.62
ASST
-35.33%
$1.00
BITF
+25.47%
$5.26
IONZ
-35.04%
$2.21
BYND
-47.01%
$1.06
NVTS
+23.51%
$10.16
JOBY
+2.94%
$16.76
DNN
+6.94%
$3.07
CAN
+33.93%
$1.45
SNAP
-7.15%
$7.78
QBTS
+23.97%
$40.93
INTC
+2.03%
$37.11
GPUS
-12.50%
$0.41
WULF
-0.58%
$13.51
F
+1.27%
$11.55
AXDX
-61.36%
$0.03
BBD
+1.30%
$3.10
CLF
+4.66%
$13.79
TSLA
+5.01%
$434.23
QS
+16.36%
$17.10
CRML
+56.07%
$23.38
NIO
+6.59%
$7.15
ETHD
-11.62%
$3.37
ACHR
+6.09%
$12.70
AMD
+0.40%
$215.76
PWM
+12.50%
$1.17
SOUN
+10.25%
$19.14
RXRX
+4.41%
$5.55
CIFR
+19.77%
$20.32
MP
+21.94%
$95.52
LAES
+13.49%
$6.14
APLD
+2.14%
$34.71
BTBT
+5.58%
$3.97
SOFI
+4.45%
$27.35
DVLT
-12.36%
$1.66
TLRY
+0.58%
$1.73
USAR
+17.01%
$38.15
DFLI
+41.35%
$1.54
ONDS
+18.43%
$10.92
PFE
-0.30%
$24.70
RR
+7.85%
$6.38
WBD
-3.22%
$17.10
QUBT
+12.85%
$21.46
ABAT
+33.25%
$8.99
NAK
+26.47%
$2.56
UAMY
+35.91%
$16.59
RMBL
+60.50%
$3.21
EOSE
+23.62%
$17.08
IREN
+8.04%
$64.58
EPWK
-8.00%
$0.08
ADD
-25.47%
$0.05
ADAP
-0.64%
$0.18
CORZ
+2.66%
$18.52
UUUU
+18.40%
$24.08
AAL
+1.51%
$11.69
RIG
+3.24%
$3.18
MARA
+9.43%
$20.40
TMQ
-9.46%
$5.93
NAKA
-4.05%
$0.83
PLTR
+0.84%
$176.92
SRM
+53.27%
$10.30
NOK
-1.79%
$5.22
IONQ
+18.72%
$83.88
RF
+1.75%
$24.58
BMNR
+7.40%
$56.35
GDXD
-12.99%
$0.74
XCH
+119.76%
$1.81
T
-1.06%
$25.59
QSI
+26.28%
$2.10
BULL
+1.62%
$11.58
NB
+3.81%
$10.78
CLSK
+2.49%
$19.76
BINI
-55.00%
$0.63
MULN
-55.00%
$0.63
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
AMZN
+1.81%
$220.30
AVGO
-5.90%
$324.63
NEHC
-8.12%
$2.60
WLGS
-5.57%
$0.04
BTG
+3.87%
$5.27
WWR
0.00%
$1.98
KDLY
-7.21%
$0.87
AMC
+0.68%
$2.95
ETWO
0.00%
$3.30
AAPL
+1.24%
$248.32
HOOD
+1.03%
$140.40
PMAX
+44.78%
$3.75
HPE
+2.76%
$25.07
TMC
+18.40%
$10.52
ABEV
+1.42%
$2.14
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.